FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
update
/
details

Agilus Diagnostics Launches Pharmacogenomics Testing Service to Revolutionize Personalized Medicine

NextEdge Admin

08 Oct 2024

2 min 0 sec

Pharmacogenomics Testing,Oncology,Psychiatry

Agilus Diagnostics has introduced a groundbreaking Pharmacogenomics Testing Service that promises to revolutionize patient care across the country. This innovative service provides healthcare providers and patients with critical insights into how individual genetic profiles affect medication response, enabling a more personalized and effective approach to treatment.

Dr. Anand K, Managing Director & CEO of Agilus Diagnostics, highlighted the significance of this launch, stating, "With the rising incidence of diseases such as cancer, cardiovascular disorders, and diabetes, our service leverages advanced genome sequencing technology to offer tailored treatment strategies that can greatly improve patient outcomes."

Pharmacogenomics is also transforming psychiatric care, offering new possibilities for understanding the genetic factors behind psychiatric disorders and treatment responses. This personalized approach to medication selection and dosing holds great promise for enhancing patient outcomes in mental health care, making treatments more effective and individualized.

Agilus' comprehensive pharmacogenomics panel, based on whole exome sequencing, covers 59 PGx genes and 194 drugs, with clinical annotations and dosing guidelines for 32 genes. The panel spans multiple specialties, including oncology, cardiology, psychiatry, neurology, and more. The reports adhere to standard dosing guidelines from key sources such as CPIC and DPWG, providing actionable insights for a wide range of medications.